Macrophages are key players in atherosclerotic lesions, regulating the local inflammatory milieu and plaque stability by the secretion of many inflammatory molecules, growth factors and cytokines. Monocytes have long been considered to be the main source of plaque macrophages. However, recent findings provide evidence for proliferation of local macrophages or transdifferentiation from other vascular cells as alternative sources. Recent years of research focused on the further identification and characterisation of macrophage phenotypes and functions. In this review we describe the advances in our understanding of monocyte and macrophage heterogeneity and its implications for specific therapeutic interventions, aiming to reduce the ever growing significant risk of cardiovascular events without any detrimental side effects on the patient's immune response.
Introduction
Atherosclerosis is the major underlying pathology of most cardiovascular diseases, though it usually remains asymptomatic for many years. Clinical complications such as stroke or myocardial infarction represent a large social and economic burden and are the leading cause of death worldwide (WHO | The top 10 causes of death). Present treatment strategies are focusing on the reduction of hyperlipidaemia using statins (Endo, 1992; Ray and Cannon, 2005) and hypertension using β-blocker and ACE inhibitors (Sipahi et al., 2007; Yusuf et al., 2008) . However, even though the combinatorial use of these treatments and surgical intervention reduces the cardiovascular risk to 30%, this disease and its outcome still stress the need for additional therapeutic options.
Atherosclerosis is characterised as a disease caused by dysfunctions in lipid metabolism and inflammation (reviewed by Hansson et al., 2006; Ross, 1999) . The discovery of inflammation as an important driver of plaque growth and rupture suggested that the immune system might be an interesting therapeutic target. Immune cells, and especially macrophages, are highly abundant in the atherosclerotic plaque and have been implicated in all stages of disease (reviewed by Hansson and Hermansson, 2011) . Upon injury of the endothelial layer (e.g. by hyperlipidaemia, hypertension, blood flow disturbances or oxidative stress), monocytes enter the vessel wall and differentiate into macrophages. Lipids accumulated and modified in the intima are engulfed by macrophages which subsequently become lipid-laden foam cells that cannot emigrate from the vessel wall anymore and thus form an early subendothelial lesion. Extensive uptake of lipids by macrophages induces their apoptosis, and while in early stages of the disease macrophages are still able to clean dead cells and cell debris in a process called efferocytosis, more advanced plaques have defective efferocytosis, leading to an accumulation of dead cells, secondary necrosis and the formation of a necrotic core. Smooth muscle cells that migrate from the media into the intima are overlaying the necrotic core and form a fibrous cap which stabilises the plaque. In an advanced plaque, the fibrous cap is destabilised by matrix metalloproteinases (MMPs) and matrix degrading enzymes secreted by macrophages increasing the risk for plaque rupture. The opposing roles of macrophages during atherogenesis, on the one hand promoting plaque growth and rupture by the creation and maintenance of an inflammatory environment and on the other hand containing the inflammation through efferocytosis and secretion of anti-inflammatory mediators, show that this cell type controls the delicate balance that determines clinical outcome. Previous studies have unveiled the broad heterogeneity of monocytes and macrophages and the differential contribution of distinct subsets to atherosclerosis. This review will highlight and update the role of these different subsets in the initiation and progression of atherosclerosis. Moreover, we will discuss promising therapeutic approaches targeting macrophage subsets or -functions to reduce the risk for cardiovascular events.
Monocytes

Characterisation of monocytes
Monocytes were first described as mononuclear phagocytes originating from the bone marrow (Furth and Cohn, 1968) . They have been seen as a homogeneous cell population that differentiates into macrophages or dendritic cells after migration into various tissues (León et al., 2005; Virolainen, 1968) . The differential expression of the lipopolysaccharide (LPS) receptor cluster of differentiation (CD) 14 and the FcγIII receptor CD16 have later shown first evidences of a heterogeneous population in humans. The major group of monocytes expresses high levels of CD14 (CD14 ++ /CD16 -) whereas the additionally described subpopulation of monocytes shows a low density of CD14 in co-expression with CD16 (CD14 + /CD16 + ) (Passlick et al., 1989 (Hilgendorf et al., 2014; Sunderkotter et al., 2004; Yona et al., 2013 (Rogacev et al., 2015) . Besides their described differences in the expression of CD14 and CD16 or Ly6C, monocyte subsets also exhibit disparities in their phenotypic and functional properties. Classical monocytes represent the major subset of circulating monocytes. They exhibit a high expression of the chemokine receptors CCR2, CXCR1, CXCR2 and CXCR4 and high levels of CD62L (Ancuta et al., 2003; Wong et al., 2011) , while both CX3CR1 and CCR5 are expressed at lower levels (Stec et al., 2012; Wong et al., 2011) . Stimulating them with LPS activates the production of several cytokines and chemokines, including Interleukins (IL)−10, IL-6, IL-8, IL-1β, Tumor Necrosis Factor (TNF) and CCL2 (Cros et al., 2010; Wong et al., 2011) , and transcriptome analysis further revealed the importance of classical monocytes in the antimicrobial immune response. This is underlined by the high expression of myeloperoxidase and several receptors such as CD36, CD32, CD64 and signal-regulatory protein alpha (SIRPα) implicated in phagocytosis. Furthermore, genes associated with angiogenesis and coagulation are enriched in this subset, linking classical monocytes to tissue repair and wound healing (Cros et al., 2010; Wong et al., 2011; Zawada et al., 2011) . Similarly, intermediate monocytes are characterised by the expression of CCR1, CCR2 and CXCR2. In addition, this subset expresses CX3CR1 and CCR5 (Ancuta et al., 2003; Zawada et al., 2011) which is expressed by non-classical monocytes. CD14 + /CD16 + monocytes have been described as main producers of reactive oxygen species (Cros et al., 2010; Zawada et al., 2011) and produce high amounts of the pro-inflammatory cytokines TNF and IL-1β upon LPS stimulation. In contrast, they were also discovered as the main source for the anti-inflammatory IL-10 (Skrzeczynska-Moncznik et al., 2008) . Furthermore, it was observed that intermediate monocytes revealed the highest expression of MHC class II compared to the classical and nonclassical subset together with a strong capability to stimulate proliferation of CD4 + T cells (Wong et al., 2011; Zawada et al., 2011) .
The characterisation of intermediate monocytes with a mixed expression of markers of classical and non-classical subset especially underlines the transitional state of these cells in the development of the different monocyte subsets. Early studies on non-classical monocyte subsets unveiled phagocytic capacities and the production of reactive oxygen species. In contrast, their cytokine production capacity was strongly reduced (Ziegler-Heitbrock et al., 1991) . Furthermore, the expression of Intercellular Cell Adhesion Molecule (ICAM)−1, opsonin receptors FcγRI and FcγRII, high levels of MHC class II and decreased expression of CD11b and CD33 suggested a more mature phenotype of non-classical monocytes, similar to differentiated macrophages that already reside in the tissue (Ziegler-Heitbrock et al., 1993) . They do not express CCR2 and CD62L but instead high levels of CX3CR1 (Ancuta et al., 2003; Wong et al., 2011) . The high expression of genes associated with cytoskeleton mobility implicated non-classical monocytes in patrolling the blood circulation to control and remove virally infected or damaged cells (Auffray et al., 2007; Wong et al., 2011; Zawada et al., 2011) . In response to Toll Like Receptors TLR7 and TLR8 activation by viruses and nucleic acids, non-classical monocytes produce TNF, IL-1β and CCL3 (Cros et al., 2010) stressing their role as surveillants in the circulation.
Monocytes in atherosclerosis
2.2.1. Monocytes as risk factor for atherosclerosis Previous studies already demonstrated an association of monocytes with atherosclerosis in humans. First evidence of a link with atherosclerosis revealed the positive correlation between the number of nonclassical monocytes and elevated levels of cholesterol, Low Density Lipoproteins (LDL) and triglycerides (Rothe et al., 1999 (Rothe et al., , 1996 . Later studies unveiled a significant role for CD16 + monocytes in atherosclerosis, illustrated by the correlation of levels of CD16 + monocytes with obesity and diabetes, two classical risk factors for atherosclerosis (Poitou et al., 2011; Timmerman et al., 2008) and the link between CD16 + monocyte levels and the diagnosis of coronary atherosclerosis (Schlitt et al., 2004) . Likewise, patients with stable or unstable angina pectoris revealed a relationship between enhanced levels of CD16 + monocytes and the presence of vulnerable atherosclerotic plaques Kashiwagi et al., 2010 (Rogacev et al., 2012) . Contrary, a study analysing frozen monocytes of 700 randomly selected subjects concluded that the classical subset is an independent predictor of future cardiovascular risk. In contrast to intermediate CD14 + /CD16 + monocytes that affect the plaque size, CD14 ++ /CD16 -monocytes were associated with inflammation and a thinner fibrous cap (Berg et al., 2012) . Nevertheless, the fact that intermediate monocytes produce high amounts of reactive oxygen species, TNF and IL-1β and stimulate CD4 + T cells, in combination with the observed association with atherosclerosis indicate monocytes as risk factor for CVD.
Monocyte recruitment
Considering the availability of (receptor) knockouts and their suitability to perform bone marrow transplantations, cell depletion or adoptive transfer, studies on monocyte recruitment are mainly performed in mice. In the steady state, monocytes mainly originate from hematopoietic stem and progenitor cells (HSPCs) in the bone marrow. However, during atherosclerosis HSPCs migrate from the bone marrow niche to seed the spleen where extramedullary haematopoiesis contributes to the generation of Ly6C high monocytes as well (Robbins et al., HSPC migration to the spleen and increases the production of splenic monocytes that results in aggravation of atherosclerosis and increases the risk for further cardiovascular events (Dutta et al., 2012) . These splenic monocytes indeed showed inflammatory properties and were shown to infiltrate the atherosclerotic lesion . The release of splenic monocytes into the circulation relies on angiotensin II (Leuschner et al., 2010) and splenic B cells (Mellak et al., 2015) . Blocking this release was shown to have beneficial effects on myocardial infarction (Leuschner et al., 2010) . In contrast, Ly6C high monocytosis was associated with impaired infarct healing . Studies on monopoieses discovered a regulatory effect of the granulocyte macrophage colony-stimulating factor/interleukin-3 receptor on HSPC proliferation in bone marrow and spleen (Wang et al., 2014a) . In atherosclerosis, the major risk factors hyperlipidaemia and reduced levels of HDL promote the proliferation of HSPCs and monocytosis (Tolani et al., 2013) whereas HDL and ATP-binding cassette transporters inhibit the proliferation of HSPCs (Yvan-Charvet et al., 2010) . In addition, hyperglycaemia, another risk factor for atherosclerosis, revealed an increased number of monocytes by sustained proliferation of granulocyte macrophage progenitors (GMPs) and common myeloid progenitors (CMPs) in diabetic mice . As a consequence of monocytosis, specifically the number of circulating Ly6C high monocytes increases (Cochain et al., 2015; Swirski et al., 2007) . Studies also revealed an increase in Ly6C high monocytes as atherosclerosis proceeds in mice (Swirski et al., 2006) suggesting a crucial role of Ly6C high monocytes in the progression of the disease.
Indeed, the inhibition of Ly6C high monocyte recruitment to plaques results in reduced plaque size, macrophage content and apoptosis (Potteaux et al., 2011) . Interestingly, the depletion of monocytes in general leads to a reduction of atherosclerosis in early stages of atherosclerosis but has no effect on established plaques (Stoneman et al., 2007) suggesting a crucial role for monocytes in early atherogenesis but a more complex situation in advanced stages. The chemokine/receptor pathway of CCL2/CCR2 is the main mechanism for the release of monocytes from the bone marrow into the blood circulation (Combadière et al., 2008; Serbina and Pamer, 2006) . The recruitment of Ly6C high , the major precursor of plaque macrophages in early lesions, to the plaque mainly depends on CCR2 as well as on CCR5 and CX3CR1 (Combadière et al., 2008; Swirski et al., 2007; Tacke et al., 2007) and leukocyte adhesion molecules expressed on endothelial cells (Gerhardt and Ley, 2015) . Indeed, blocking of CCR2, CCR5 and CX3CR1 abolishes atherosclerosis development in mice (Combadière et al., 2008) while the expression of CCR5 was shown to associate with atherosclerosis progression (González et al., 2001 ). In addition, a deficiency of the transcription factor Bmal1 exacerbated atherosclerosis by increasing the recruitment of Ly6C high monocytes to the lesion and by a preferential differentiation to a pro-inflammatory macrophage phenotype (Huo et al., 2017) . Whereas Ly6C high monocytes are extensively implicated in atherosclerosis, the contribution of Ly6C low monocytes to atherosclerosis is still unknown. A recently published mouse model with Nr4a1 enhancer deficiency (Thomas et al., 2016) gives the opportunity to separately investigate Ly6C low monocytes without compromising the immune functions Nr4a1 is involved in.
In conclusion, Ly6C high monocytes, either derived from bone marrow or from extramedullary haematopoiesis, are preferentially recruited suggesting an important role for monocyte recruitment in the formation of atherosclerotic lesions in mice and blocking this recruitment has been shown to reduce atherosclerosis.
Macrophages
Characterisation of macrophage subsets
Similarly to the heterogeneity of monocytes, also macrophages form a heterogeneous population driven by environmental stimuli. At first, the macrophage M1 and M2 paradigm was introduced as a parallel to the opposing T h 1 and T h 2 phenotypes in T helper cells (Mills et al., 2000) . Later, macrophage heterogeneity described by the classical and alternative activation of macrophages (Gordon, 2003) , became synonymous with this M1 and M2 dichotomy (Mantovani et al., 2004) . Overall, the terminology of M1/M2 macrophages represents just an oversimplification of macrophage polarisation. Due to an almost infinite combination of possible stimuli, the macrophage phenotype is highly heterogeneous, for which reason the M1 and M2 polarisation should only be considered as two opposing phenotypes within a multidimensional spectrum. Although the M1/M2 model is based on in vitro observations and may not completely hold true for all in vivo settings, especially in the case of atherosclerosis, it still provides a useful, yet simplified way to illustrate and describe macrophage polarisation and heterogeneity.
The classical (M1) activation of macrophages is induced by the cytokines TNF and IFNγ or by microbial products such as LPS (Boldrick et al., 2002; Dalton et al., 1993) . As a result, these activated macrophages produce pro-inflammatory cytokines such as IL-1β, IL-6, IL-12, IL-23 and TNF as well as low levels of anti-inflammatory IL-10 (Mosser, 2003; Verreck et al., 2004) . In combination with the secretion of reactive oxygen species and nitric oxide (NO) produced by the inducible nitric oxide synthase (iNOS)-mediated conversion of L-arginine, the classical activation of macrophages comprises an inflammatory response against microbial infections (Gordon, 2003) . However, an uncontrolled inflammatory response can cause serious tissue damage, and the alternatively activated M2 macrophages represent the counterbalancing, anti-inflammatory subset and is responsible for dampening inflammation (Murray and Wynn, 2011) . This anti-inflammatory subset is associated with tissue repair, angiogenesis and fibrosis (Jetten et al., 2014; Lee et al., 2001) . In subsequent years, it was further divided into three different subclasses: M2a, M2b, and M2c. Upon activation by IL-4 and IL-13, M2a macrophages are producing IL-10 in contrast to low levels of IL-12 while expressing high levels of the mannose receptor (CD206) and the pro-fibrotic factors fibronectin and Transforming Growth Factor (TGF) β, thus representing the subset associated with fibrosis and wound healing (Delavary et al., 2011; Spencer et al., 2010) . Instead of iNOS-mediated production of NO, M2a macrophages express Arginase-1 that converts L-arginine into L-ornithine and L-proline, required for collagen synthesis (Gordon, 2003) . Immune complexes or TLR activation in combination with IL-1β or LPS induce the polarisation of M2b macrophages (Mosser and Edwards, 2010) . Similar to M2c macrophages which are polarised by IL-10, TGFβ or glucocorticoids, M2b macrophages express high levels of the receptor proto-oncogene tyrosine-protein kinase MER (MerTK) underlining their increased phagocytic capacity and their immune regulatory functions (Mosser, 2003; Zizzo and Cohen, 2013) . Upon activation, M2b macrophage express high levels of the anti-inflammatory cytokine IL-10 ( Mosser and Edwards, 2010) . Over the last years, additional polarisation states were described. M2d macrophage polarisation is mediated by IL-6 and adenosine A 2A receptor activation, inducing the expression of IL-10 and vascular endothelial growth factor (VEGF) and reducing the expression of TNF and IL-12 (Ferrante et al., 2013; Grinberg et al., 2009) .
The polarisation of macrophages is modulated through the activation of transcription factors and signalling pathways downstream from the receptors for the different inducers. The key pathways in macrophage polarisation are STAT1/6-signalling, NF-κB signalling, PI3K/Akt and the MAPK/ERK pathway. Activation of STAT-1 via IFNγ receptor induces the expression of genes associated with an M1 phenotype, whereas the activation of STAT-3/STAT-6 promotes the expression M2-related genes (Darnell et al., 1994; Lang et al., 2002; Pauleau et al., 2004) . The NF-κB signalling mediates the initiation as well as the resolution of inflammation via its diverse family members p50, p52, p65, RelB and c-Rel which form different homo-and heterodimers (Lawrence et al., 2001) , with a pro-inflammatory phenotype in macrophages that is mainly induced via p65 whereas an activation of p50 is associated with the anti-inflammatory phenotype (Bonizzi and Karin, 2004; Porta et al., 2009 ). PI3K/Akt signalling is induced by the activation of several receptors such as the IL-4 receptor and various chemokine receptors and the different isoforms of PI3K or Akt were shown to influence polarisation of murine macrophages in a specific way (recently reviewed by Vergadi et al., 2017) . The isoforms of PI3K are associated with either M1 (p110δ) or M2 phenotype (p110α, β, γ) (Lee et al., 2007 (Lee et al., , 2015 Wang et al., 2014b) . In addition, while Akt2 has been implicated in the polarisation of M1 macrophages, it has been shown that Akt1 is mediating the polarisation to the M2 macrophages (Androulidaki et al., 2009; Arranz et al., 2012) . In addition, the MAPK/ ERK pathway has already been linked to inflammation (Schindler et al., 2003) . In line with this, it has recently been shown that the polarisation of macrophages towards an anti-inflammatory phenotype via IL-4 is mediated by the inhibition of the MAPK signalling pathway (Zhao et al., 2016) .
Macrophage subsets in atherosclerosis 3.2.1. Origin of plaque macrophages
Macrophages are the most abundant type of immune cells in the atherosclerotic plaque. As described above, monocyte recruitment is crucial for the formation of the plaque and the number of circulating monocytes has thus been shown to directly correlate with the number of macrophages in the plaque (Combadière et al., 2008) . For many years, these circulating cells were regarded as the origin of all plaque macrophages (Swirski et al., 2006) and although not substantiated, it was believed that the classical, pro-inflammatory Ly6 high or CD14 ++ / CD16 -subset lead to M1 macrophages, while the non-classical monocyte subsets contribute to the M2 subsets. However, recent studies have shown that in some inflammatory conditions, local proliferation of resident macrophages can drive the accumulation of macrophages (Robbins et al., 2013; Schulz et al., 2012) . In atherosclerosis, proliferating macrophages were already monitored in the 90 s (Rekhter and Gordon, 1995; Rosenfeld and Ross, 1990) . Indeed, later studies revealed that oxLDL can promote proliferation of macrophages in vitro (Hamilton et al., 1999; Martens et al., 1998) . Local proliferation of macrophages in atherosclerosis has been a topic of debate for the last few years. Local proliferation has been shown to be a prominent feature in macrophage accumulation in advanced atherosclerosis contributing to~87% of accumulating macrophages (Guo et al., 2005; Robbins et al., 2013) . In contrast, others reported that proliferation in early lesions is higher than in advanced lesions (Lhoták et al., 2016) , although it has to be considered that the also highly proliferative smooth muscle cells (SMCs) in the plaque can express macrophage markers, which makes it difficult to distinguish true macrophage proliferation (Feil et al., 2014; Shankman et al., 2015) . This SMC transdifferentiation has first been observed in the late 90s, describing SMCs expressing the macrophage marker CD68 (Andreeva et al., 1997) . It has then been exhibited that cholesterol-loading induces the transdifferentiation of SMCs to macrophage-like cells (Rong et al., 2003) and more recently, it has been shown that approximately 50% of foam cells might have a SMC origin (Allahverdian et al., 2014) . To unveil whether macrophages transdifferentiate into SMCs or vice versa, Feil et al. employed a genetic lineage tracing model in mice (Feil et al., 2014) showing SMCs to lose their cell type-specific markers and convert to macrophage-like cells. However, these data have to be seen with caution. Firstly, although it is generally accepted that macrophages can express SMC marker and vice versa, in case of Feil et al., it is still not completely confirmed if the labelled cells are fully converted into macrophages, exerting macrophage (-like) functions. Secondly, the expression of CD68 or Mac-2 is not limited to macrophages, i.e. CD68 is also expressed by other myeloid cells, while T cells and various stromal cells can also express Mac-2.
The phenotypic conversion has been shown to be dependent on the transcription factor Kruppel-like factor Klf4 (Shankman et al., 2015) . Although these macrophage-like cells can become foam cells, they are functionally different and reveal a different transcriptional profile with a reduced phagocytosis and efferocytosis capacity (Feil et al., 2014; Shankman et al., 2015; Vengrenyuk et al., 2015) and are reconverted into a SMC phenotype upon cholesterol depletion.
Localisation of macrophage subsets in the plaque
The plaque displays a microenvironment with a large amount of stimuli potentially driving macrophage phenotypic diversity. However, little is known about the specific localisation of different subsets within the plaque. Given that the number of both M1 and M2 macrophages increases during the progression of atherosclerosis in humans (Stöger et al., 2012) , it has been hypothesised that the balance between the proand anti-inflammatory macrophages is crucial for the stability of human atherosclerotic plaques. The part of the lesion covered by the fibrous cap is considered to be the most stable part of the plaque, and here the relative numbers of M1 and M2 macrophages are equal (Stöger et al., 2012) . In agreement, Chinetti-Gbaguidi et al. have shown that M2 macrophages are present in more stable areas of the plaque, co-localising with high levels of M2-inducing IL-4 (Chinetti-Gbaguidi et al., 2011). Contrary, the shoulders of the plaque are more prone to rupture (Barlis et al., 2008) and contain mainly M1 macrophages (Stöger et al., 2012) . This distribution suggests that the high protease activity of M1 macrophages is counterbalanced at stable sites by the pro-fibrotic and anti-inflammatory activity of M2 macrophages, whereas at ruptureprone sites this balance shifts towards the more pro-inflammatory M1 subtype. In mice, such studies have not been reported yet.
Atherosclerosis-specific macrophage subsets and related functions
The initially described subsets of pro-inflammatory M1 and antiinflammatory M2 macrophages represent two extremes in a macrophage polarisation continuum (Mantovani et al., 2004) . However, these observations were mainly made in vitro and thus fail to reflect the complexity of microenvironments in vivo. Specifically in atherosclerosis, a broad range of cytokines and growth factors are present and macrophages are exposed to these factors which highly affect their phenotype and polarisation state (Wolfs et al., 2011) .
Two major growth factors mediating the differentiation and polarisation of macrophages are macrophage colony stimulating factor (M-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF), inducing M2 and M1 macrophages, respectively (Wolfs et al., 2011) . Besides M-CSF and GM-CSF, many pro-and anti-inflammatory cytokines and mediators are found in the atherosclerotic plaque (Tedgui and Mallat, 2006) . The pro-inflammatory cytokines TNF and IFNγ show proatherogenic effects, mediating the M1 polarisation of plaque macrophages, further enhancing expression of pro-inflammatory cytokines and protease activity of macrophages (Quillard et al., 2011; Ramji and Davies, 2015) . On the other hand, anti-inflammatory cytokines, e.g. IL-4, IL-10 and IL-13, generally exert anti-atherogenic effects by inducing an anti-inflammatory M2 phenotype in plaque macrophages. Moreover, IL-10 and IL-13 have an atheroprotective effect by limiting monocyte recruitment (Cardilo-Reis et al., 2012; Potteaux et al., 2004) . Besides reducing pro-inflammatory cytokine production, IL-10 was shown to reduce MMP expression and modulate lipid metabolism in macrophages (Han and Boisvert, 2015) . Accumulated lipids are ingested by macrophages via scavenger receptors, e.g. CD36 and SRA1, but lipoprotein particles can also trigger pro-inflammatory signalling pathways via activation of TLRs (Björkbacka et al., 2004; Edfeldt et al., 2002; Monaco et al., 2004) . Studies revealed an interaction between CD36 and TLR-4/−6 that induces a pro-inflammatory profile in response to oxLDL (Lee et al., 2012; Stewart et al., 2010) . OxLDL has also been shown to induce a Klf2-mediated shift in macrophage phenotype from an anti-to a pro-inflammatory phenotype, leading to the expression of pro-inflammatory cytokines IL-6 and IL-18 and the chemokine CCL2. Similarly, the polarisation of a 'Mox' subset has been suggested, which is induced by the uptake of oxidised phospholipids and mediated by the transcription factor nuclear erythroid-2 related factor (Nrf2) (Kadl et al., 2010) . Consequently, M1 associated genes such as IL-1β and Cox-2 are upregulated through the TLR2 pathway (Kadl et al., 2011 (Kadl et al., , 2010 .
Next to its important role in the ingestion of lipids, CD36 is also involved in the inflammatory effect of cholesterol crystals by supporting the formation and nucleation of insoluble crystals and the priming and activation of the NLRP-3 inflammasome leading to the production of the pro-inflammatory cytokines IL-1β and IL-18 (Duewell et al., 2010; Sheedy et al., 2013) . Reverse cholesterol transport, mediated by ATP-binding cassette transporters such as ABCA1 and ABCG1 and by high density lipoproteins (HDL), has also been shown to modulate macrophage inflammatory responses. A deficiency in ABCA1 and ABCG1 in hyperlipidemic mice leads to a pro-inflammatory phenotype in macrophages . Studies on effects of HDLinduced cholesterol depletion in macrophages, however, have shown conflicting results (van der Vorst et al., 2017a), including both proinflammatory (van der Vorst et al., 2017b) as well as anti-inflammatory effects (De Nardo et al., 2014) .
Other macrophage subsets recently described in the context of atherosclerosis are the M4, Mhem and M(Hb). The M4 macrophage subset is induced by CXCL4 and identified by the expression of MMP7 and the calcium binding protein S100A8 (Erbel et al., 2015) . In this subset, CXCL4 induces a downregulation of the atheroprotective receptor CD163 (Gleissner et al., 2010) . The Mhem and M(Hb) subsets are induced by heme and haemoglobin, respectively (Boyle et al., 2012; Finn et al., 2012) . These subsets are resistant to lipid accumulation and foam cell formation and exhibit an anti-inflammatory phenotype and thus an atheroprotective effect (Boyle et al., 2012; Philippidis et al., 2004) .
In brief, macrophages respond to many stimuli affecting their function and phenotype in the atherosclerotic plaque. In general, stimuli inducing a pro-inflammatory response in macrophages contribute to the inflammatory milieu in the plaque and fuel the progression of atherosclerosis. Therefore, inhibiting these pro-inflammatory responses or enhancing anti-inflammatory responses received much attention as therapeutic strategies to reduce cardiovascular events.
Therapeutic targets
Targeting recruitment, proliferation and general macrophage functions
Currently available therapeutic approaches are focusing on the reduction of hyperlipidaemia and hypertension, with significant though still limited success rates. The well-known pharmaceutical family of statins was shown to dramatically reduce the number of clinical events (Assmann et al., 1999) , not only by lowering the circulating levels of cholesterol but also by exerting anti-inflammatory effects such as reduction in monocyte recruitment (Jain and Ridker, 2005) . The U.S. Food and Drug Administration and European Medicine Agency also approved PCSK9 inhibitors which lower cholesterol levels by decreased degradation of the LDL receptor (Lagace et al., 2006) . Treatment with the PCSK9-blocking antibody evolocumab has indeed recently been shown to reduce the LDL levels and thereby their risk of cardiovascular events (Sabatine et al., 2017) . Similarly, evinacumab or antisense oligonucleotide mediated inhibition of ANGPTL3 lowered patients' plasma lipid levels and decreased the odds of atherosclerosis in experimental models (Dewey et al., 2017 , Graham et al., 2017 .
The recently published results from the Canakinumab Antiinflammatory Thrombosis Outcome Study (CANTOS), a large and highly anticipated IL-1β antibody treatment trial that targeted the inflammatory nature of atherosclerosis in myocardial infarction patients without affecting lipidaemia, showed a significant reduction in the reoccurrence of clinical manifestations of atherosclerosis (Ridker et al., 2017) . However, a concomitant increase in severe infections and the treatment's enormous cost-benefit ratio make this approach an unviable option for prevention or even therapy. Similarly, other trials intervening at the level of cytokines or cytokine receptors will be at risk of lacking disease specificity, and thus additional strategies influencing the immune system in a more targeted way are still to be pursued in order to complement lipid-lowering approaches. Considering the pivotal role of macrophages in atherosclerosis, their recruitment, differentiation, polarisation, proliferation, apoptosis and efferocytosis might serve as promising therapeutic targets (Fig. 1) .
As described above, the inhibition of monocyte numbers or their recruitment has been shown to have a beneficial effect on atherosclerosis. The clodronate-loaded liposome-mediated depletion of monocytes is an abrasive way shown to reduce atherosclerosis development in rabbits (Ylitalo et al., 1994) . In mice, depletion of Ly6C high monocytes and neutrophils via antibodies showed an inhibition of macrophage accumulation in transplant arteriosclerosis (Schiopu et al., 2012) . The blocking of chemokines or adhesion molecules, either on monocytes or on endothelial cells, to obstruct monocyte recruitment has been extensively studied in the past (reviewed by e.g. Koenen and Weber, 2010; Lutters et al., 2004) . However, the inhibition of general monocyte recruitment to the site of inflammation can have severe side effects on the host's immune response against infections. Before being useful as a therapeutic approach, additional research is necessary aiming to identify targets or approaches to rather block monocyte recruitment specifically to the atherosclerotic plaque. One possibility, recently published, is an antibody against oxLDL that inhibits the expression of CCL2 in monocytes and macrophages resulting in the regression of the atherosclerotic plaque mainly by reduction of cell infiltration (Schiopu et al., 2007; Su et al., 2017) . Oligomeric proanthecyanidins, isolated from the plant species Crataegus oxyacantha, have been shown to inhibit the differentiation of monocytes into macrophages in vitro and in vivo in rats by downregulating the proinflammatory NF-κB pathway (Mohana et al., 2015) , which could provide another means to inhibit macrophage accumulation. Moreover, a macrophage-specific nanoparticle-delivery of simvastatin has been shown to suppress the proliferative capacity of macrophages and therefore, to reduce the accumulation of macrophages in the plaque, resulting in reduced plaque inflammation and alleviation of atherosclerosis (Tang et al., 2015) . It remains to be determined, however, whether this effect is merely due to the suppression of macrophage proliferation. In contrast to blocking monocyte recruitment, targeting the differentiation of monocytes to macrophages and the proliferation of macrophages in the plaque showed no compromising effects on the immune response. Although the inhibition of proliferation revealed interesting findings, we still lack knowledge about proliferating macrophages in the atherosclerotic plaque. It has to be determined whether a specific subset is proliferating to define whether inhibition or even stimulation of the proliferating subsets has a beneficial effect.
Contrary to the limited knowledge on proliferation in macrophages, atherosclerosis-associated functions of macrophages and their impact are quite well understood and possible negative side effects are better predictable. Targeting the lipid uptake and cholesterol homeostasis in macrophages has been extensively studied and indeed effects on macrophage phenotype, cytokine production and atherosclerosis have been observed, at least in mice. Deficiencies for the scavenger receptors SRA1 and CD36 were protective against atherosclerosis in mice through the inhibition of foam cell formation (Febbraio et al., 2000; Suzuki et al., 1997) . Moreover, an increased cholesterol efflux for example induced by compound K (20-O-b-d-glucopyranosyl-20(S)-protopanaxadiol, a major component of Panax notoginseng saponins), resulted in reduced inflammation and reduced formation of atherosclerotic plaques (Zhou et al., 2016) . The activation of the nuclear receptor LXR receptor via LXR agonists enhances the cholesterol efflux and promotes an anti-inflammatory phenotype of macrophagesresulting in a reduced lesion area (Joseph et al., 2002) . In addition, cyclodextrin (cyclic oligosaccharide 2-hydroxypropyl-β-cyclodextrin, a substance that can solubilise cholesterol and dissolve cholesterol crystals) was shown to promote plaque regression via an enhanced reverse cholesterol transport and the induction of an anti-inflammatory phenotype in macrophages (Zimmer et al., 2016) . However, the contradictory effects of cholesterol depletion by HDL on macrophage inflammatory responses indicate the complexity of such therapeutic interventions.
Natural IgM antibodies against oxidation epitopes have been shown to exist, that enhance not only the clearance of oxidised lipids, thereby reducing atherosclerosis (Binder et al., 2003) , but may also enhance the clearance of apoptotic cells (Binder, 2010) . In this line, it has been observed that a reduced capacity of efferocytosis worsens atherosclerosis (Ait-Oufella et al., 2007; Thorp et al., 2008) . Recently, restoration of the impaired capacity to phagocytose apoptotic cells has gained attention as a novel therapeutic means. Pitavastin treatment was shown to enhance efferocytosis by activation of ERK5 resulting in suppressed plaque formation (Heo et al., 2014) . Furthermore, Kojima et al. reported that blocking of the 'don't eat me signal' CD47 via antibodies increased efferocytosis and even reduced existing atherosclerosis (Kojima et al., 2016) . A different strategy is the transfer of apoptotic cells, which has also resulted in a reduction of atherosclerosis (Frodermann et al., 2015; Hosseini et al., 2015) .
To fulfill their diverse functions, macrophages reprogram and adapt their metabolism in response to the microenvironment (Biswas and Mantovani, 2012) . In line with this, it has been indicated that both M1 and M2 macrophages have specific metabolic signatures. M1 macrophages show enhanced glycolysis and fatty acid synthesis whereas M2 macrophages are characterised by fatty acid oxidation and a decreased glycolysis (reviewed by Geeraerts et al., 2017) . It has recently been revealed in macrophages that the upregulation of the fatty acid oxidation via miR-33 shifts pro-inflammatory macrophages towards an anti-inflammatory phenotype resulting in reduced atherosclerosis in mice .
Targeting macrophage polarisation/subpopulations 4.2.1. Modulating inducers of polarisation
Compared to targeting above described specific macrophage functions, the modulation of polarisation states in plaque macrophages aims at the induction of a set of anti-atherogenic functions. Previously, we showed a positive effect of polarised macrophages in a hind limb ischaemia model where the adoptive transfer of in vitro M1, M2a and M2c polarised macrophages promotes reperfusion recovery (Jetten et al., 2013) . Interestingly, the recovery is mediated by both M1 and M2 macrophages due to their expression of TNF-α or FGF-2, respectively, which have each been linked to pro-angiogenic properties (Ligresti et al., 2011; Yang et al., 1996) . Various studies focused on in vivo polarisation of macrophages using specific knockout mouse models of polarising stimuli, e.g. cytokine receptors. Mice reconstituted with TNF receptor (TNFR)-deficient bone marrow developed smaller lesions and smaller areas of macrophage foam cells (Xanthoulea et al., 2008) . Most interestingly, TNFR deficiency also induced an anti-inflammatory environment by a reduced expression of the pro-inflammatory CCL2. Surprisingly, IFNγ receptor deficiency did not affect atherosclerosis development in mice . Lin et al. showed that in vivo transfection of an IL4-R agonist induced T h 2 and M2 marker expression and significantly attenuated atherosclerosis development in ApoE -/-mice (Lin et al., 2015) . While IL-10 receptor deficiency resulted in a more pro-inflammatory macrophage phenotype in vitro, myeloid IL-10 receptor deficiency in vivo significantly reduced atherosclerosis development, which was attributed to enhanced intestinal cholesterol efflux (Stöger et al., 2016) . Also compounds to induce an anti-inflammatory phenotype and mediate anti-atherogenic functions were already used. Helminth-derived antigens have been shown to reduce atherosclerosis by mediating an anti-inflammatory polarisation of macrophages. The injection of soluble egg antigens in LDLr -/-mice induced the expression of anti-inflammatory IL-10 and reduced the expression of pro-inflammatory cytokines resulting in a protection against atherosclerosis (Wolfs et al., 2014) . Similar effects were also observed in mice injected with heat-killed S. Aureus where reduced atherosclerosis was monitored due to an induction of an anti-inflammatory macrophages phenotype (Frodermann et al., 2016) . Sphingosine-1-phosphate (S1P), a bioactive lipid mediator often carried by HDL, has been shown to induce anti-inflammatory IL-4 secretion and signalling, i.e. inducing a M2 phenotype (Park et al., 2014) , although it remains to be determined whether these effects are indeed atheroprotective in vivo. Pioglitazone-incorporated nanoparticles have shown to stabilize the atherosclerotic plaque by shifting the polarisation of macrophages to an anti-inflammatory profile associated with a reduced production of inflammatory cytokines and matrix metalloproteinases (Nakashiro et al., 2016) .
Transcriptional modulation of polarisation
Members of the STAT-, NF-κB-and PI3K/Akt-signalling have been demonstrated to modulate macrophage polarisation and contribute to an inflammatory or anti-inflammatory environment in the atherosclerotic plaque. Studies which assessed the knockout of the isoforms Akt1, Akt2 and Akt3 have shown different effects of these distinct isoforms on macrophage polarisation and atherosclerosis. A deficiency for Akt1 in ApoE -/-mice has revealed an increase in atherosclerosis caused by accelerated inflammation and an increased apoptosis in macrophages and endothelial cells (Fernández-Hernando et al., 2007) . Similarly, a knockout of Akt3 in ApoE -/-mice promoted foam cell formation resulting in increased atherosclerosis (Ding et al., 2012) . A knockout of Akt1 in LDLr -/-, however, did not show any effect (Babaev et al., 2014) . In contrast, LDLR -/-mice deficient for Akt2 have shown a decrease in atherosclerosis due to a M2 polarisation of macrophages and reduced foam cell formation (Babaev et al., 2014; Rotllan et al., 2015) . The anti-diabetic drugs metformin and exenatide revealed anti-inflammatory effects by regulating MAPK and NF-κB in human monocytes and macrophages (Buldak et al., 2016) . In contrast, the inhibition of NF-κB activation in macrophages was also shown to have a negative effect on atherosclerosis. Increased atherosclerosis with advanced lesions was observed possibly resulting from a misbalance between the pro-and anti-inflammatory macrophages (Kanters et al., 2003) .
As expected, deficiency for STAT1 has been shown to reduce atherosclerosis development in mice, which was attributed to reduced foam cell formation and enhanced macrophage apoptosis (Agrawal et al., 2007; Lim et al., 2008) . On the other hand, gene delivery of STAT3, which in one for the M2 polarising transcription factors, reduced monocyte/macrophage burden in aortic vessels of LDLr -/-mice (Khan et al., 2010) , while deficiency for STAT3β exacerbated atherosclerosis development in ApoE -/-mice (Lee et al., 2013) . Moreover, the anti-inflammatory and atheroprotective effects of S1P were shown to be mediated by STAT6 signalling (Park et al., 2014) , although the effect of STAT6 deficiency itself on atherosclerosis remains to be determined. The suppression of transcription cofactor interferon regulatory factor 2-binding protein 2 (IRF2BP2) has been associated with ischemic heart diseases in human and increased atherosclerosis with inflammatory macrophages in mice. Reduced expression of IRF2BP2 is furthermore linked to a decreased Klf2 expression. Restoring Klf2 levels in IRF2BP2 deficient mice has been shown to induce an anti-inflammatory phenotype in macrophages which identifies enhancing IRF2BP2 or Kfl2 as an interesting target . The nuclear receptor Nur77 has also been shown to induce an anti-inflammatory phenotype in macrophage. Mice deficient for Nur77 have exhibited an increased activation of the NF-κB member p65 and thus increased polarisation towards M1 macrophages. Therefore, an increased expression of Nur77 might serve as a target to mediate an anti-inflammatory phenotype and reduce atherosclerosis (Hanna et al., 2012) .
Targeting the polarisation pathways of macrophages can shift the balance of macrophages from a pro-inflammatory to an anti-inflammatory profile resulting in a shift towards an atheroprotective subset of macrophages. However, signalling pathways and especially transcription factors involved in polarisation can also affect additional cell functions and processes such as the immune response.
Conclusion and future perspectives
Monocytes and macrophages take part in various mechanisms of formation, progression and destabilisation of the atherosclerotic plaque. Exposure to the complex microenvironment of the plaque, with a plethora of stimuli, induces different polarisation states in macrophages and shifts their phenotype and functions. Therefore, influencing macrophage polarisation to avoid pro-atherogenic and improve antiatherogenic functions represents a promising approach to influence the disease course. Targeting general monocyte/macrophage recruitment or macrophage functions e.g. by broadly modulating transcription factors or mediators of pathways that polarise macrophages can also negatively affect immune response or other functions of macrophages that are beneficial in atherosclerosis. Therefore, we need to continue our understanding of macrophage origin, phenotype and specific macrophage (subset) function in order to inhibit detrimental/enhance beneficial macrophage functions only to reduce the risk of cardiovascular events.
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